Immunogenicity and safety study of Boostrix in pregnant women.

Phase 1

• Conditions: Booster immunisation against diphtheria, tetanus and pertussis diseases. The study population for this study will include pregnant women.; MedDRA version: 20.1Level: LLTClassification code 10047976Term: Whooping cough due to bordetella pertussis (B. pertussis)System Organ Class: 100000004862; MedDRA version: 20.0Level: LLTClassification code 10009663Term: Clostridium tetani infectionSystem Organ Class: 100000004862; MedDRA version: 20.0Level: LLTClassification code 10054237Term: Corynebacterium diphtheriae infectionSystem Organ Class: 100000004862; Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

• Registration Number: EUCTR2014-001119-38-IT
• Lead Sponsor: GLAXOSMITHKLINE BIOLOGICALS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-02-27
• Last Update Posted: 12 March 2018

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: 680

Inclusion Criteria

• Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards,
return for follow-up visits); • Written informed consent obtained from the subject prior to
performing any study specific procedure, as per local regulations; • A healthy pregnant woman between, and including, 18 and 45 years of
age at the time of screening; • Pregnant subjects at 270/7-366/7 weeks (completed 27 weeks but
not 37 weeks) of gestation at the time of vac-cination (Visit 1), as established by ultrasound examination.
• Not at high risk for complications, as determined by the obstetrical algorithm for identification of eligible subjects and the Obstetrical Risk Assessment Form;
• No significant foetal abnormalities, as observed by the level II ultrasound testing conducted after 18 weeks of gestation; • Nuchal translucency scan, serum testing and any other prenatal tests,
if conducted, should suggest normal preg-nancy.
• Willing to have the infant born immunised with Infanrix hexa and Prevenar 13, as per national recommendations, in the follow-up clinical
studies DTPA (BOOSTRIX)-048 PRI and DTPA (BOOSTRIX)-049 BST: 048; • Subjects who do not plan to give their child for adoption or place the
child in care.
Are the trial subjects under 18? no
Number of subjects for this age range: 1
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 680
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Subjects diagnosed with multiple pregnancies (twins, triplets etc.) • Previous vaccination containing diphtheria, tetanus or pertussis antigens or diphtheria and tetanus toxoids at any time during the current pregnancy •Women with co-morbid medical or obstetric conditions that in the opinion of the investigator have the potential to complicate the
pregnancy course and outcomes •Gestational diabetes as determined by glucose tolerance test conducted after 20 weeks of gestation, as per
local recommendations of the country •History of early onset (<34 weeks of gestation) of eclampsia/pre-eclampsia in previous pregnancy •
History of major congenital anomalies in previous pregnancies •Use of any investigational or non-registered product other than the study
vaccine anytime during the current pregnancy or planned use during the study period • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe •Chronic
administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 6 months prior to the 1st vaccine. For corticosteroids,
this will mean prednisone >= 20 mg/day, or equivalent. Inhaled and topical steroids are allowed •Administration of long-acting immunemodifying
drugs at any time during the study period •Planned
administration/administration of a vaccine not foreseen by the study protocol in the period within the period starting 30 days before and 30
days after the dose of vaccine with the exception of seasonal influenza vaccine that can be administered anytime during the study period •
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an
investigational or a non-investigational vaccine/product •Serious underlying medical condition •History of an encephalopathy of unknown
aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine •History of transient thrombocytopenia or
neurological complications following an earlier immunisation against
diphtheria and/or tetanus •Significant mental illness •Family history (1st degree relatives only) of congenital anomalies, recurrent pregnancy
losses (2 or more consecutive losses) and unexplained neonatal death(s)
in the subject •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical
examination •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine •History of febrile illness
within the past 72 hours •History of physician-diagnosed or laboratory confirmed pertussis within the past 5 years • Anything that would
prevent subject from completing the study or put the subject at risk, as determined by the investigator •Acute disease and/or fever at the time
of enrolment •Administration of immunoglobulins and/or any blood products within the 3 months preceding the dose of study vaccine, or planned administration during the study period, with the exception of anti-D (Rh)-immunoglobulin •History of chronic excessive alcohol consumption and/or drug abuse.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified